Merdad Parsey Sells 2,000 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILD) insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now directly owns 96,380 shares in the company, valued at $6,614,559.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Gilead Sciences Trading Down 0.3 %

Shares of NASDAQ GILD opened at $68.40 on Wednesday. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $87.86. The firm has a market capitalization of $85.22 billion, a PE ratio of 190.00, a PEG ratio of 2.92 and a beta of 0.18. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. The business has a 50-day moving average price of $66.01 and a two-hundred day moving average price of $72.42.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The firm had revenue of $6.69 billion during the quarter, compared to analyst estimates of $6.36 billion. During the same period last year, the company posted $1.37 EPS. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. As a group, analysts predict that Gilead Sciences, Inc. will post 3.75 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, June 27th. Stockholders of record on Friday, June 14th were issued a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, June 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.50%. Gilead Sciences’s dividend payout ratio is 855.56%.

Analysts Set New Price Targets

GILD has been the topic of a number of research analyst reports. Royal Bank of Canada reissued a “sector perform” rating and set a $74.00 price target on shares of Gilead Sciences in a report on Monday. Oppenheimer reissued an “outperform” rating and set a $105.00 price target on shares of Gilead Sciences in a report on Friday, April 19th. Morgan Stanley lowered their price target on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a report on Friday, April 26th. StockNews.com raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Finally, Robert W. Baird reaffirmed a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a report on Thursday, June 20th. Twelve research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Hold” and a consensus price target of $83.47.

Institutional Investors Weigh In On Gilead Sciences

Several institutional investors have recently made changes to their positions in the company. Modus Advisors LLC lifted its holdings in shares of Gilead Sciences by 10.8% during the 2nd quarter. Modus Advisors LLC now owns 9,810 shares of the biopharmaceutical company’s stock valued at $673,000 after buying an additional 960 shares during the last quarter. Massmutual Trust Co. FSB ADV raised its stake in shares of Gilead Sciences by 72.6% in the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 4,487 shares of the biopharmaceutical company’s stock valued at $308,000 after acquiring an additional 1,887 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Gilead Sciences by 56.0% in the 2nd quarter. GAMMA Investing LLC now owns 9,940 shares of the biopharmaceutical company’s stock valued at $682,000 after acquiring an additional 3,567 shares in the last quarter. Abich Financial Wealth Management LLC increased its position in Gilead Sciences by 88.4% in the 1st quarter. Abich Financial Wealth Management LLC now owns 2,219 shares of the biopharmaceutical company’s stock worth $163,000 after buying an additional 1,041 shares during the period. Finally, Keynote Financial Services LLC bought a new position in Gilead Sciences in the 1st quarter worth approximately $845,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.